InvestorsHub Logo
Followers 22
Posts 3682
Boards Moderated 0
Alias Born 07/20/2006

Re: None

Saturday, 07/27/2024 3:44:59 PM

Saturday, July 27, 2024 3:44:59 PM

Post# of 3059
FWIW -

It still is a big IF that ENTA wins summary judgment against PFIZER. Even a mediated settlement is quite positive.

Back in June of 2022, RBC Capital Markets analyst Brian Abrahams states -

"A typical royalty rate might be in the 6% range, which on sales of Paxlovid's magnitude, could be more than $1 billion annually in its peak years and may speak to why it might be worth Enanta's time and expenses to pursue this," he said in a report to clients.

https://www.investors.com/news/technology/enta-stock-launches-as-enanta-causes-a-kerfuffle-for-pfizer-paxlovid/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News